Treatment of LRTIs: Two antimicrobials compared

Infections in Medicine

Volumn 15, Issue 4, 1998, Pages

  Castellano, Michael A ^a   Maniatis, Theodore ^a  

^a STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

Author keywords

Ampicillin sulbactam; Cefoxitin; Infection, bacterial; Infection, lower respiratory tract

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; CEFOXITIN; CEFUROXIME; SULBACTAM; SULTAMICILLIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFECTION RISK; INTRAVENOUS DRUG ADMINISTRATION; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE;

EID: 0031981640     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Chow JW, Yu VL: Antibiotic studies in pneumonia. Chest 96:453-455, 1989.
2. Cunha BA: Ampicillin/sulbactam in lower respiratory tract infections: A review. Clin Ther 13:714-726, 1991.
3. Gleeson K, Reynolds HY: Life-threatening pneumonia. Clin Chest Med 15:581-602, 1994.
4. McKellar P: Treatment of community-acquired pneumonias. Am J Med 79:25-31, 1985.
5. Bergogne-Berezin E: Continuous activity of significant antibiotics. Clin Ther 13:181-187, 1991.
6. Doern GV: Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med 99(suppl 6B):S3-S7, 1995.
7. English AR, Retsema JA, Girard AE, et al: CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactamases: Initial bacteriological characterization. Antimicrob Agents Chemother 14:414-419, 1978.
8. Retsema JA, English AR, Girard AE: CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae and Bacteroides. Antimicrob Agents Chemother 17:615-622, 1980.
9. Jones RN: In vitro evaluation of aminopenicillin/beta-lactamase inhibitor combinations. Drugs 35(suppl 7):S17-S26, 1988.
10. Valcke YJ, Rosseel MT, Pauwels RA, et al: Penetration of ampicillin and sulbactam in the lower airways during respiratory infections. Antimicrob Agents Chemother 34:958-962, 1990.
11. Wildfeuer A, Ruhle KH, Boleskei PL, et al: Kinetics of ampicillin and sulbactam: Concentrations of ampicillin and sulbactam in serum and various compartments of the respiratory tract of patients. Infection 22:149-151, 1994.
12. Wexler HM, Harris B, Carter WT, et al: In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria. Antimicrob Agents Chemother 27:876-882, 1985.
13. Crombleholme WR, Ohm-Smith M, Robbie MO, et al: Ampicillin/sulbactam versus metronidazole-gentamicin in the treatment of soft tissue pelvic infections. Am J Obstet Gynecol 156:507-512, 1987.
14. Castellano MA: Sulbactam/ampicillin in the treatment of lower respiratory infections. Drugs 35(suppl 7):S53-S56, 1988.
15. Guneren MF: Clinical experience with intramuscular sulbactam/ampicillin in the outpatient treatment of various infections. Drugs 35:57-68, 1988.
16. Hemsell DL, Bawdon RE, Hemsell PG, et al: Single-agent therapy for acute pelvic inflammatory disease: Sulbactam/ampicillin versus cefoxitin. J Int Med Res 18(suppl 4):S85-S89, 1990.
17. Geckler R: A comparison of ampicillin/ sulbactam and cefuroxime in the treatment of patients with bacterial infections of the lower respiratory tract. Clin Ther 16:662-672, 1994.
18. National Committee for Clinical Laboratory Standards: Alternative methods for antimicrobial susceptibility testing of anaerobic bacteria. Villanova, Pa., NCCLS Publ. M17-P, 1988.